Recently, the U.S. Food and Drug Administration approved talazoparib with enzalutamide for a particularly aggressive form of prostate cancer (homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer).

The news should be encouraging for patients with this diagnosis, Health First Urologist Alejandra Guevara Mendez told Vero News.

The news for all men everywhere is, follow the U.S. Preventive Services Task Force guidance about prostate cancer screening.

If you’re a person with a first-degree relative (father or brother) who has had a prostate cancer diagnosis, consider genetic testing and begin getting screened at 40, Dr. Guevara Mendez said.

This new two-drug treatment is usually well-tolerated, the doctor said, but “it’s important to share any side effects with your doctor.”

“Patients sometimes fear that if they say they’re dealing with side effects, their doctor will take them off medication. … Your doctor will always weigh risk against reward, so be open and honest in your conversations.”

READ the full health feature, and learn more about the largest-scale prostate cancer study ever conducted, in Vero News HERE.